Key result
Intravenous immunoglobulin, heart failure therapy, and an ICD led to successful clinical recovery in a patient with idiopathic inflammatory myopathy who presented with sudden cardiac arrest.
Why the study?
Cardiomyopathy and rapid progressive interstitial pneumonia are potentially fatal complications in dermatomyositis with limited treatment data for cardiomyopathy.
Case Report (n=1)
May support IVIg in dermatomyositis cardiomyopathy; hypothesis-generating and leaves open randomized confirmation.
Cardiomyopathy and rapid progressive interstitial pneumonia (IP) are potentially fatal complications in polymyositis/dermatomyositis. We experienced a dermatomyositis patient with multiple adverse prognostic factors, complicating rapid progressive IP, macrophage activation syndrome (MAS), and cardiomyopathy. IP and MAS improved with strong immunosuppressive therapy, despite which cardiomyopathy developed. Therefore, we applied intravenous high-dose immunoglobulin therapy (IVIg), and cardiac function improved dramatically. This is the first report to present the effectiveness of IVIg for cardiomyopathy in dermatomyositis.
No takes yet. Share an insight, caveat, or question.
Yoshimatsu et al. (2015) conducted a case report in Myocarditis secondary to idiopathic inflammatory myopathy (IIM) (n=1). Intravenous immunoglobulin (IVIG) was evaluated. Intravenous immunoglobulin, heart failure therapy, and an ICD led to successful clinical recovery in a patient with idiopathic inflammatory myopathy who presented with sudden cardiac arrest.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: